Page last updated: 2024-08-25

lamifiban and Cardiovascular Stroke

lamifiban has been researched along with Cardiovascular Stroke in 21 studies

Research

Studies (21)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	11 (52.38)	18.2507
2000's	10 (47.62)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Califf, RM; Crater, SW; Giugliano, RP; Green, CL; Harrington, RA; Johanson, P; Krucoff, MW; Langer, A; Lincoff, AM; Newby, LK; Rebeiz, AG; Roe, MT; Topol, EJ; Wagner, GS	1
Gawaz, M; Neumann, FJ; Schömig, A	1
Rossi, G	1
Adgey, AA	1
Armstrong, PW; Braunwald, E; Califf, RM; Gibler, WB; Hamm, CW; Maseri, A; Simoons, ML; Van de Werf, F	1
Bates, ER	1
Greenbaum, AB; Harrington, RA; Hudson, MP; Ohman, EM	1
Chanu, B	1
Phillips, J; Stouffer, GA; Subbarao, VD	1
White, HD	1
Moliterno, DJ	1
Califf, RM; Lincoff, AM; Topol, EJ	1
Jang, IK; Sabatine, MS	1
Mak, KH; Moliterno, DJ	1
Goto, S; Handa, M; Ikeda, Y; Murata, M	1
Bode, C; Nordt, TK; Peter, K	1
Boden, WE; McKay, RG	1
Barrabés, JA; Blanco, J; Garcia-Dorado, D; Lidón, RM; Mirabet, M; Pizcueta, P; Puigfel, Y; Ruiz-Meana, M; Soler-Soler, J; Soriano, B	1

Reviews

13 review(s) available for lamifiban and Cardiovascular Stroke

Article	Year
[Platelet membrane glycoproteins as site of pharmacological intervention in the treatment of coronary disease]. Deutsche medizinische Wochenschrift (1946), 1997, Oct-02, Volume: 122, Issue:40 Topics: Abciximab; Acetates; Alkynes; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Binding Sites; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Coronary Disease; Double-Blind Method; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Platelet Membrane Glycoproteins; Randomized Controlled Trials as Topic; Receptors, Antigen, B-Cell; Receptors, Cell Surface; Time Factors; Tirofiban; Tyrosine	1997
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. European heart journal, 1998, Volume: 19 Suppl D Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Atherectomy, Coronary; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Survival Analysis; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine	1998
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. European heart journal, 1998, Volume: 19 Suppl D Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine	1998
Platelet glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Current opinion in cardiology, 1998, Volume: 13, Issue:4 Topics: Abciximab; Acetates; Antibodies, Monoclonal; Blood Coagulation; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Treatment Outcome; Tyrosine	1998
Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction. Journal of thrombosis and thrombolysis, 1999, Volume: 7, Issue:3 Topics: Abciximab; Acetates; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dogs; Double-Blind Method; Drug Evaluation, Preclinical; Drug Therapy, Combination; Eptifibatide; Fibrinogen; Fibrinolytic Agents; Forecasting; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Pilot Projects; Plasminogen Activators; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Tyrosine	1999
Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. The American journal of the medical sciences, 1999, Volume: 318, Issue:2 Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Angina, Unstable; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine	1999
Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies? The Journal of invasive cardiology, 2000, Volume: 12 Suppl A Topics: Acetates; Angina, Unstable; Anticoagulants; Confidence Intervals; Controlled Clinical Trials as Topic; Enoxaparin; Female; Humans; Male; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Survival Rate; Treatment Outcome; Tyrosine	2000
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. Journal of the American College of Cardiology, 2000, Volume: 35, Issue:5 Topics: Abciximab; Acetates; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Combined Modality Therapy; Coronary Disease; Drug Monitoring; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Patient Selection; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Recurrence; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine	2000
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. The American journal of medicine, 2000, Aug-15, Volume: 109, Issue:3 Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine	2000
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Current cardiology reports, 1999, Volume: 1, Issue:3 Topics: Acetates; Acute Disease; Eptifibatide; Hemorrhage; Humans; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Tirofiban; Tyrosine	1999
A new approach to antiplatelet therapy: inhibitor of GPIb/V/IX-vWF interaction. Haemostasis, 2000, Volume: 30 Suppl 3 Topics: Acetates; Adenosine Diphosphate; Animals; Antibodies, Monoclonal; Arterial Occlusive Diseases; Collagen; Drug Evaluation, Preclinical; Epinephrine; Epitopes; Genetic Predisposition to Disease; Guinea Pigs; Hemorheology; Humans; Integrins; Liposomes; Macromolecular Substances; Myocardial Infarction; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Polymorphism, Genetic; Receptors, Collagen; Recombinant Fusion Proteins; Stress, Mechanical; Thrombosis; Tyrosine; von Willebrand Factor	2000
[GPIIb/IIIa blockers for optimizing thrombolysis in acute myocardial infarct]. Herz, 2001, Volume: 26 Suppl 1 Topics: Abciximab; Acetates; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Plasminogen Activators; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator; Tyrosine	2001
Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials. Current opinion in cardiology, 2001, Volume: 16, Issue:6 Topics: Acetates; Clinical Trials as Topic; Electrocardiography; Eptifibatide; Heart Conduction System; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine	2001

Trials

5 trial(s) available for lamifiban and Cardiovascular Stroke

Article	Year
International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Gl Circulation, 1998, Jun-23, Volume: 97, Issue:24 Topics: Acetates; Aged; Angina, Unstable; Anticoagulants; Aspirin; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Survival Analysis; Tyrosine	1998
Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. Journal of the American College of Cardiology, 1998, Volume: 32, Issue:7 Topics: Acetates; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fibrinolysis; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Treatment Outcome; Tyrosine	1998
[Inhibitors of GPIIb/IIIa platelet receptors]. Archives des maladies du coeur et des vaisseaux, 1999, Volume: 92, Issue:7 Topics: Abciximab; Acetates; Antibodies, Monoclonal; Cerebrovascular Disorders; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine	1999
Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee. American heart journal, 2000, Volume: 139, Issue:4 Topics: Acetates; Adult; Aged; Cohort Studies; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Survival Rate; Tyrosine	2000
Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation, 2002, Jan-22, Volume: 105, Issue:3 Topics: Acetates; Acute Disease; Aged; Coronary Disease; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Titrimetry; Treatment Outcome; Tyrosine	2002

Other Studies

3 other study(ies) available for lamifiban and Cardiovascular Stroke

Article	Year
Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). The American journal of cardiology, 2005, Mar-01, Volume: 95, Issue:5 Topics: Abciximab; Acetates; Aged; Antibodies, Monoclonal; Clinical Trials as Topic; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Streptokinase; Survival Analysis; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome; Tyrosine	2005
[Superaspirin in the platelet aggregation inhibitor therapy]. Recenti progressi in medicina, 1997, Volume: 88, Issue:12 Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Integrins; Myocardial Infarction; Oligopeptides; Peptides, Cyclic; Platelet Aggregation Inhibitors; Recurrence; Sulfoxides; Thiazolidines; Time Factors; Tyrosine	1997
Lack of effect of glycoprotein IIb/IIIa blockade on myocardial platelet or polymorphonuclear leukocyte accumulation and on infarct size after transient coronary occlusion in pigs. Journal of the American College of Cardiology, 2002, Jan-02, Volume: 39, Issue:1 Topics: Acetates; Animals; Female; Hemodynamics; Male; Myocardial Infarction; Myocardial Reperfusion; Neutrophils; Peroxidase; Platelet Aggregation; Platelet Aggregation Inhibitors; Swine; Tyrosine	2002